IQVIA Holdings Inc. $IQV Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 4.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 983,436 shares of the medical research company’s stock after selling 40,549 shares during the quarter. Bank of New York Mellon Corp’s holdings in IQVIA were worth $221,676,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of IQV. Ameliora Wealth Management Ltd. acquired a new stake in shares of IQVIA in the 4th quarter valued at $25,000. International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the 4th quarter valued at $27,000. Westside Investment Management Inc. raised its stake in IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after acquiring an additional 101 shares in the last quarter. Measured Wealth Private Client Group LLC acquired a new stake in IQVIA during the 3rd quarter worth $30,000. Finally, Activest Wealth Management raised its stake in IQVIA by 590.0% during the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after acquiring an additional 118 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Down 1.8%

Shares of IQVIA stock opened at $183.56 on Friday. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. IQVIA Holdings Inc. has a 1 year low of $147.62 and a 1 year high of $247.04. The company has a market capitalization of $30.64 billion, a P/E ratio of 22.75, a P/E/G ratio of 1.60 and a beta of 1.21. The business has a 50 day moving average price of $172.12 and a 200 day moving average price of $194.94.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same period in the previous year, the firm posted $2.70 EPS. The company’s quarterly revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has initiated a stock repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target on the stock in a research note on Friday, March 6th. Royal Bank Of Canada initiated coverage on IQVIA in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 target price for the company. Truist Financial decreased their target price on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. Citigroup decreased their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. Finally, TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and upped their target price for the company from $174.00 to $213.00 in a research report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $224.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.